nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentamidine—CYP3A5—Sorafenib—thyroid cancer	0.0886	0.173	CbGbCtD
Pentamidine—CYP2C8—Sorafenib—thyroid cancer	0.0852	0.167	CbGbCtD
Pentamidine—CYP2C19—Sorafenib—thyroid cancer	0.0715	0.14	CbGbCtD
Pentamidine—CYP1A2—Sorafenib—thyroid cancer	0.066	0.129	CbGbCtD
Pentamidine—CYP3A4—Vandetanib—thyroid cancer	0.0573	0.112	CbGbCtD
Pentamidine—CYP2D6—Sorafenib—thyroid cancer	0.0544	0.106	CbGbCtD
Pentamidine—CYP3A4—Sorafenib—thyroid cancer	0.0346	0.0676	CbGbCtD
Pentamidine—CYP2D6—Doxorubicin—thyroid cancer	0.033	0.0645	CbGbCtD
Pentamidine—CYP3A4—Doxorubicin—thyroid cancer	0.021	0.041	CbGbCtD
Pentamidine—S100B—MyD88:Mal cascade initiated on plasma membrane—CDK1—thyroid cancer	0.00142	0.0164	CbGpPWpGaD
Pentamidine—S100B—MyD88-independent cascade—CDK1—thyroid cancer	0.00136	0.0157	CbGpPWpGaD
Pentamidine—CYP1A1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00133	0.0154	CbGpPWpGaD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.0013	0.015	CbGpPWpGaD
Pentamidine—S100B—Activated TLR4 signalling—CDK1—thyroid cancer	0.00122	0.0141	CbGpPWpGaD
Pentamidine—CYP2C8—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00122	0.0141	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 4 (TLR4) Cascade—CDK1—thyroid cancer	0.00115	0.0133	CbGpPWpGaD
Pentamidine—CYP2C19—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00109	0.0126	CbGpPWpGaD
Pentamidine—CYP4A11—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00105	0.0121	CbGpPWpGaD
Pentamidine—CYP4A11—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00104	0.012	CbGpPWpGaD
Pentamidine—S100B—Toll-Like Receptors Cascades—CDK1—thyroid cancer	0.00102	0.0118	CbGpPWpGaD
Pentamidine—Arthralgia—Sorafenib—thyroid cancer	0.000978	0.00243	CcSEcCtD
Pentamidine—Myalgia—Sorafenib—thyroid cancer	0.000978	0.00243	CcSEcCtD
Pentamidine—Ventricular tachycardia—Epirubicin—thyroid cancer	0.000971	0.00242	CcSEcCtD
Pentamidine—S100B—Signaling by ERBB4—CDK1—thyroid cancer	0.000965	0.0112	CbGpPWpGaD
Pentamidine—Dry mouth—Sorafenib—thyroid cancer	0.000957	0.00238	CcSEcCtD
Pentamidine—Hyperkalaemia—Epirubicin—thyroid cancer	0.000954	0.00237	CcSEcCtD
Pentamidine—Diarrhoea—Vandetanib—thyroid cancer	0.000951	0.00237	CcSEcCtD
Pentamidine—Melaena—Epirubicin—thyroid cancer	0.000949	0.00236	CcSEcCtD
Pentamidine—Creatinine increased—Doxorubicin—thyroid cancer	0.000944	0.00235	CcSEcCtD
Pentamidine—Salivary hypersecretion—Epirubicin—thyroid cancer	0.000943	0.00235	CcSEcCtD
Pentamidine—Anaphylactic shock—Sorafenib—thyroid cancer	0.000938	0.00233	CcSEcCtD
Pentamidine—Colitis—Epirubicin—thyroid cancer	0.000933	0.00232	CcSEcCtD
Pentamidine—Infection—Sorafenib—thyroid cancer	0.000932	0.00232	CcSEcCtD
Pentamidine—Candida infection—Epirubicin—thyroid cancer	0.000927	0.00231	CcSEcCtD
Pentamidine—Skin exfoliation—Epirubicin—thyroid cancer	0.000927	0.00231	CcSEcCtD
Pentamidine—Shock—Sorafenib—thyroid cancer	0.000923	0.00229	CcSEcCtD
Pentamidine—Gait disturbance—Doxorubicin—thyroid cancer	0.000921	0.00229	CcSEcCtD
Pentamidine—Dizziness—Vandetanib—thyroid cancer	0.000919	0.00229	CcSEcCtD
Pentamidine—Thrombocytopenia—Sorafenib—thyroid cancer	0.000918	0.00228	CcSEcCtD
Pentamidine—Blood urea increased—Epirubicin—thyroid cancer	0.000917	0.00228	CcSEcCtD
Pentamidine—CYP4A11—PPAR Alpha Pathway—CCND1—thyroid cancer	0.000917	0.0106	CbGpPWpGaD
Pentamidine—Neuropathy—Epirubicin—thyroid cancer	0.000912	0.00227	CcSEcCtD
Pentamidine—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.000899	0.00224	CcSEcCtD
Pentamidine—Anorexia—Sorafenib—thyroid cancer	0.000894	0.00222	CcSEcCtD
Pentamidine—Vomiting—Vandetanib—thyroid cancer	0.000884	0.0022	CcSEcCtD
Pentamidine—Hyperkalaemia—Doxorubicin—thyroid cancer	0.000883	0.0022	CcSEcCtD
Pentamidine—Mouth ulceration—Epirubicin—thyroid cancer	0.000878	0.00218	CcSEcCtD
Pentamidine—Melaena—Doxorubicin—thyroid cancer	0.000878	0.00218	CcSEcCtD
Pentamidine—Rash—Vandetanib—thyroid cancer	0.000876	0.00218	CcSEcCtD
Pentamidine—Dermatitis—Vandetanib—thyroid cancer	0.000876	0.00218	CcSEcCtD
Pentamidine—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.000873	0.00217	CcSEcCtD
Pentamidine—Headache—Vandetanib—thyroid cancer	0.000871	0.00217	CcSEcCtD
Pentamidine—Colitis—Doxorubicin—thyroid cancer	0.000863	0.00215	CcSEcCtD
Pentamidine—Candida infection—Doxorubicin—thyroid cancer	0.000858	0.00213	CcSEcCtD
Pentamidine—Skin exfoliation—Doxorubicin—thyroid cancer	0.000858	0.00213	CcSEcCtD
Pentamidine—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000857	0.00991	CbGpPWpGaD
Pentamidine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000854	0.00212	CcSEcCtD
Pentamidine—Blood urea increased—Doxorubicin—thyroid cancer	0.000848	0.00211	CcSEcCtD
Pentamidine—CYP4A11—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000848	0.00981	CbGpPWpGaD
Pentamidine—CYP1A2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000848	0.00981	CbGpPWpGaD
Pentamidine—Neuropathy—Doxorubicin—thyroid cancer	0.000844	0.0021	CcSEcCtD
Pentamidine—Sepsis—Epirubicin—thyroid cancer	0.000843	0.0021	CcSEcCtD
Pentamidine—Dyspnoea—Sorafenib—thyroid cancer	0.000836	0.00208	CcSEcCtD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.000829	0.00959	CbGpPWpGaD
Pentamidine—Nausea—Vandetanib—thyroid cancer	0.000826	0.00205	CcSEcCtD
Pentamidine—Dyspepsia—Sorafenib—thyroid cancer	0.000825	0.00205	CcSEcCtD
Pentamidine—Phlebitis—Epirubicin—thyroid cancer	0.000818	0.00204	CcSEcCtD
Pentamidine—Decreased appetite—Sorafenib—thyroid cancer	0.000815	0.00203	CcSEcCtD
Pentamidine—Mouth ulceration—Doxorubicin—thyroid cancer	0.000813	0.00202	CcSEcCtD
Pentamidine—Diabetes mellitus—Epirubicin—thyroid cancer	0.000811	0.00202	CcSEcCtD
Pentamidine—Fatigue—Sorafenib—thyroid cancer	0.000808	0.00201	CcSEcCtD
Pentamidine—Hepatic function abnormal—Epirubicin—thyroid cancer	0.000807	0.00201	CcSEcCtD
Pentamidine—Pain—Sorafenib—thyroid cancer	0.000802	0.00199	CcSEcCtD
Pentamidine—Constipation—Sorafenib—thyroid cancer	0.000802	0.00199	CcSEcCtD
Pentamidine—Eye pain—Epirubicin—thyroid cancer	0.000781	0.00194	CcSEcCtD
Pentamidine—Sepsis—Doxorubicin—thyroid cancer	0.00078	0.00194	CcSEcCtD
Pentamidine—S100B—Signaling by ERBB4—NRG1—thyroid cancer	0.000774	0.00896	CbGpPWpGaD
Pentamidine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000767	0.00191	CcSEcCtD
Pentamidine—Renal failure acute—Epirubicin—thyroid cancer	0.000764	0.0019	CcSEcCtD
Pentamidine—Phlebitis—Doxorubicin—thyroid cancer	0.000757	0.00188	CcSEcCtD
Pentamidine—Diabetes mellitus—Doxorubicin—thyroid cancer	0.00075	0.00187	CcSEcCtD
Pentamidine—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.000746	0.00186	CcSEcCtD
Pentamidine—Urticaria—Sorafenib—thyroid cancer	0.000745	0.00185	CcSEcCtD
Pentamidine—Body temperature increased—Sorafenib—thyroid cancer	0.000741	0.00184	CcSEcCtD
Pentamidine—Abdominal pain—Sorafenib—thyroid cancer	0.000741	0.00184	CcSEcCtD
Pentamidine—Renal impairment—Epirubicin—thyroid cancer	0.000741	0.00184	CcSEcCtD
Pentamidine—CYP3A5—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000727	0.00841	CbGpPWpGaD
Pentamidine—Eye pain—Doxorubicin—thyroid cancer	0.000723	0.0018	CcSEcCtD
Pentamidine—Hypoglycaemia—Epirubicin—thyroid cancer	0.000722	0.0018	CcSEcCtD
Pentamidine—Lethargy—Epirubicin—thyroid cancer	0.000719	0.00179	CcSEcCtD
Pentamidine—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000719	0.00179	CcSEcCtD
Pentamidine—Renal failure acute—Doxorubicin—thyroid cancer	0.000707	0.00176	CcSEcCtD
Pentamidine—Affect lability—Epirubicin—thyroid cancer	0.000694	0.00173	CcSEcCtD
Pentamidine—Hypersensitivity—Sorafenib—thyroid cancer	0.000691	0.00172	CcSEcCtD
Pentamidine—Renal impairment—Doxorubicin—thyroid cancer	0.000685	0.00171	CcSEcCtD
Pentamidine—Face oedema—Epirubicin—thyroid cancer	0.000681	0.00169	CcSEcCtD
Pentamidine—Asthenia—Sorafenib—thyroid cancer	0.000673	0.00167	CcSEcCtD
Pentamidine—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000668	0.00166	CcSEcCtD
Pentamidine—Mood swings—Epirubicin—thyroid cancer	0.000668	0.00166	CcSEcCtD
Pentamidine—Lethargy—Doxorubicin—thyroid cancer	0.000666	0.00166	CcSEcCtD
Pentamidine—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000666	0.00166	CcSEcCtD
Pentamidine—Pruritus—Sorafenib—thyroid cancer	0.000663	0.00165	CcSEcCtD
Pentamidine—Blood creatinine increased—Epirubicin—thyroid cancer	0.000661	0.00164	CcSEcCtD
Pentamidine—Liver function test abnormal—Epirubicin—thyroid cancer	0.000651	0.00162	CcSEcCtD
Pentamidine—Dry skin—Epirubicin—thyroid cancer	0.000646	0.00161	CcSEcCtD
Pentamidine—CYP4A11—PPARA activates gene expression—RXRA—thyroid cancer	0.000644	0.00745	CbGpPWpGaD
Pentamidine—Affect lability—Doxorubicin—thyroid cancer	0.000642	0.0016	CcSEcCtD
Pentamidine—Diarrhoea—Sorafenib—thyroid cancer	0.000642	0.0016	CcSEcCtD
Pentamidine—CYP3A5—Metapathway biotransformation—CHST14—thyroid cancer	0.000641	0.00741	CbGpPWpGaD
Pentamidine—CYP4A11—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000631	0.00729	CbGpPWpGaD
Pentamidine—Face oedema—Doxorubicin—thyroid cancer	0.00063	0.00157	CcSEcCtD
Pentamidine—Gastritis—Epirubicin—thyroid cancer	0.000624	0.00155	CcSEcCtD
Pentamidine—Dizziness—Sorafenib—thyroid cancer	0.00062	0.00154	CcSEcCtD
Pentamidine—Mood swings—Doxorubicin—thyroid cancer	0.000618	0.00154	CcSEcCtD
Pentamidine—CYP4A11—NRF2 pathway—SLC5A5—thyroid cancer	0.000611	0.00707	CbGpPWpGaD
Pentamidine—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000611	0.00152	CcSEcCtD
Pentamidine—Asthma—Epirubicin—thyroid cancer	0.000609	0.00152	CcSEcCtD
Pentamidine—Influenza—Epirubicin—thyroid cancer	0.000609	0.00152	CcSEcCtD
Pentamidine—CYP1A1—Metapathway biotransformation—CHST14—thyroid cancer	0.000606	0.007	CbGpPWpGaD
Pentamidine—Eosinophilia—Epirubicin—thyroid cancer	0.000603	0.0015	CcSEcCtD
Pentamidine—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000602	0.0015	CcSEcCtD
Pentamidine—CYP4A11—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000601	0.00695	CbGpPWpGaD
Pentamidine—Dry skin—Doxorubicin—thyroid cancer	0.000598	0.00149	CcSEcCtD
Pentamidine—Pancreatitis—Epirubicin—thyroid cancer	0.000597	0.00149	CcSEcCtD
Pentamidine—Vomiting—Sorafenib—thyroid cancer	0.000596	0.00148	CcSEcCtD
Pentamidine—Rash—Sorafenib—thyroid cancer	0.000591	0.00147	CcSEcCtD
Pentamidine—Dermatitis—Sorafenib—thyroid cancer	0.000591	0.00147	CcSEcCtD
Pentamidine—Headache—Sorafenib—thyroid cancer	0.000587	0.00146	CcSEcCtD
Pentamidine—Bronchitis—Epirubicin—thyroid cancer	0.000586	0.00146	CcSEcCtD
Pentamidine—Pancytopenia—Epirubicin—thyroid cancer	0.000579	0.00144	CcSEcCtD
Pentamidine—Gastritis—Doxorubicin—thyroid cancer	0.000577	0.00144	CcSEcCtD
Pentamidine—Neutropenia—Epirubicin—thyroid cancer	0.00057	0.00142	CcSEcCtD
Pentamidine—Asthma—Doxorubicin—thyroid cancer	0.000564	0.0014	CcSEcCtD
Pentamidine—Influenza—Doxorubicin—thyroid cancer	0.000564	0.0014	CcSEcCtD
Pentamidine—CYP2C19—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000562	0.0065	CbGpPWpGaD
Pentamidine—Eosinophilia—Doxorubicin—thyroid cancer	0.000558	0.00139	CcSEcCtD
Pentamidine—Nausea—Sorafenib—thyroid cancer	0.000557	0.00139	CcSEcCtD
Pentamidine—CYP2C8—Metapathway biotransformation—CHST14—thyroid cancer	0.000555	0.00642	CbGpPWpGaD
Pentamidine—Pancreatitis—Doxorubicin—thyroid cancer	0.000553	0.00138	CcSEcCtD
Pentamidine—Hyperglycaemia—Epirubicin—thyroid cancer	0.00055	0.00137	CcSEcCtD
Pentamidine—Drowsiness—Epirubicin—thyroid cancer	0.000543	0.00135	CcSEcCtD
Pentamidine—Bronchitis—Doxorubicin—thyroid cancer	0.000542	0.00135	CcSEcCtD
Pentamidine—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000539	0.00134	CcSEcCtD
Pentamidine—Pancytopenia—Doxorubicin—thyroid cancer	0.000535	0.00133	CcSEcCtD
Pentamidine—Renal failure—Epirubicin—thyroid cancer	0.000534	0.00133	CcSEcCtD
Pentamidine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000533	0.00132	CcSEcCtD
Pentamidine—Stomatitis—Epirubicin—thyroid cancer	0.00053	0.00132	CcSEcCtD
Pentamidine—Conjunctivitis—Epirubicin—thyroid cancer	0.000528	0.00131	CcSEcCtD
Pentamidine—Neutropenia—Doxorubicin—thyroid cancer	0.000527	0.00131	CcSEcCtD
Pentamidine—Haematuria—Epirubicin—thyroid cancer	0.000518	0.00129	CcSEcCtD
Pentamidine—CYP4A11—NRF2 pathway—RXRA—thyroid cancer	0.000514	0.00594	CbGpPWpGaD
Pentamidine—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000513	0.00593	CbGpPWpGaD
Pentamidine—Sinusitis—Epirubicin—thyroid cancer	0.00051	0.00127	CcSEcCtD
Pentamidine—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000509	0.00127	CcSEcCtD
Pentamidine—Drowsiness—Doxorubicin—thyroid cancer	0.000503	0.00125	CcSEcCtD
Pentamidine—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000498	0.00124	CcSEcCtD
Pentamidine—S100B—Immune System—RAP1GAP—thyroid cancer	0.000497	0.00574	CbGpPWpGaD
Pentamidine—Bradycardia—Epirubicin—thyroid cancer	0.000497	0.00124	CcSEcCtD
Pentamidine—CYP2C19—Metapathway biotransformation—CHST14—thyroid cancer	0.000496	0.00573	CbGpPWpGaD
Pentamidine—Renal failure—Doxorubicin—thyroid cancer	0.000494	0.00123	CcSEcCtD
Pentamidine—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000493	0.00123	CcSEcCtD
Pentamidine—Stomatitis—Doxorubicin—thyroid cancer	0.00049	0.00122	CcSEcCtD
Pentamidine—Rhinitis—Epirubicin—thyroid cancer	0.000489	0.00122	CcSEcCtD
Pentamidine—Conjunctivitis—Doxorubicin—thyroid cancer	0.000489	0.00122	CcSEcCtD
Pentamidine—Hepatitis—Epirubicin—thyroid cancer	0.000488	0.00121	CcSEcCtD
Pentamidine—S100B—Innate Immune System—LGALS3—thyroid cancer	0.000486	0.00562	CbGpPWpGaD
Pentamidine—Hypoaesthesia—Epirubicin—thyroid cancer	0.000485	0.00121	CcSEcCtD
Pentamidine—Pharyngitis—Epirubicin—thyroid cancer	0.000484	0.0012	CcSEcCtD
Pentamidine—S100B—Innate Immune System—PRKAR1A—thyroid cancer	0.000482	0.00557	CbGpPWpGaD
Pentamidine—Oedema peripheral—Epirubicin—thyroid cancer	0.000481	0.0012	CcSEcCtD
Pentamidine—Haematuria—Doxorubicin—thyroid cancer	0.000479	0.00119	CcSEcCtD
Pentamidine—CYP4A11—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000479	0.00554	CbGpPWpGaD
Pentamidine—Sinusitis—Doxorubicin—thyroid cancer	0.000472	0.00117	CcSEcCtD
Pentamidine—Erythema multiforme—Epirubicin—thyroid cancer	0.000461	0.00115	CcSEcCtD
Pentamidine—Bradycardia—Doxorubicin—thyroid cancer	0.000459	0.00114	CcSEcCtD
Pentamidine—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	0.000456	0.00527	CbGpPWpGaD
Pentamidine—Flushing—Epirubicin—thyroid cancer	0.000453	0.00113	CcSEcCtD
Pentamidine—Rhinitis—Doxorubicin—thyroid cancer	0.000452	0.00113	CcSEcCtD
Pentamidine—Hepatitis—Doxorubicin—thyroid cancer	0.000451	0.00112	CcSEcCtD
Pentamidine—CYP4A11—Biological oxidations—RXRA—thyroid cancer	0.000451	0.00521	CbGpPWpGaD
Pentamidine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000449	0.00112	CcSEcCtD
Pentamidine—Pharyngitis—Doxorubicin—thyroid cancer	0.000448	0.00111	CcSEcCtD
Pentamidine—Oedema peripheral—Doxorubicin—thyroid cancer	0.000445	0.00111	CcSEcCtD
Pentamidine—CYP4A11—NRF2 pathway—NRG1—thyroid cancer	0.000444	0.00514	CbGpPWpGaD
Pentamidine—CYP3A5—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000439	0.00508	CbGpPWpGaD
Pentamidine—Chills—Epirubicin—thyroid cancer	0.000438	0.00109	CcSEcCtD
Pentamidine—Arrhythmia—Epirubicin—thyroid cancer	0.000436	0.00108	CcSEcCtD
Pentamidine—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000434	0.00503	CbGpPWpGaD
Pentamidine—Erythema multiforme—Doxorubicin—thyroid cancer	0.000427	0.00106	CcSEcCtD
Pentamidine—Erythema—Epirubicin—thyroid cancer	0.000425	0.00106	CcSEcCtD
Pentamidine—Flushing—Doxorubicin—thyroid cancer	0.000419	0.00104	CcSEcCtD
Pentamidine—Tension—Epirubicin—thyroid cancer	0.000417	0.00104	CcSEcCtD
Pentamidine—Dysgeusia—Epirubicin—thyroid cancer	0.000416	0.00103	CcSEcCtD
Pentamidine—CYP1A1—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000415	0.0048	CbGpPWpGaD
Pentamidine—Nervousness—Epirubicin—thyroid cancer	0.000412	0.00103	CcSEcCtD
Pentamidine—CYP4A11—PPARA activates gene expression—PPARG—thyroid cancer	0.000407	0.0047	CbGpPWpGaD
Pentamidine—Chills—Doxorubicin—thyroid cancer	0.000405	0.00101	CcSEcCtD
Pentamidine—Arrhythmia—Doxorubicin—thyroid cancer	0.000403	0.001	CcSEcCtD
Pentamidine—Vision blurred—Epirubicin—thyroid cancer	0.0004	0.000995	CcSEcCtD
Pentamidine—S100B—Signaling Pathways—CALCB—thyroid cancer	0.000398	0.00461	CbGpPWpGaD
Pentamidine—CYP4A11—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000398	0.0046	CbGpPWpGaD
Pentamidine—Erythema—Doxorubicin—thyroid cancer	0.000393	0.000977	CcSEcCtD
Pentamidine—Anaemia—Epirubicin—thyroid cancer	0.000392	0.000976	CcSEcCtD
Pentamidine—S100B—Signaling by ERBB4—PTEN—thyroid cancer	0.000388	0.00449	CbGpPWpGaD
Pentamidine—CYP1A2—Metapathway biotransformation—CHST14—thyroid cancer	0.000386	0.00447	CbGpPWpGaD
Pentamidine—Tension—Doxorubicin—thyroid cancer	0.000386	0.000959	CcSEcCtD
Pentamidine—Dysgeusia—Doxorubicin—thyroid cancer	0.000385	0.000957	CcSEcCtD
Pentamidine—Nervousness—Doxorubicin—thyroid cancer	0.000382	0.000949	CcSEcCtD
Pentamidine—Vertigo—Epirubicin—thyroid cancer	0.000381	0.000949	CcSEcCtD
Pentamidine—Syncope—Epirubicin—thyroid cancer	0.000381	0.000947	CcSEcCtD
Pentamidine—CYP2C8—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000381	0.0044	CbGpPWpGaD
Pentamidine—Leukopenia—Epirubicin—thyroid cancer	0.00038	0.000945	CcSEcCtD
Pentamidine—S100B—Signaling Pathways—TRIM33—thyroid cancer	0.000378	0.00437	CbGpPWpGaD
Pentamidine—Palpitations—Epirubicin—thyroid cancer	0.000375	0.000933	CcSEcCtD
Pentamidine—Loss of consciousness—Epirubicin—thyroid cancer	0.000373	0.000928	CcSEcCtD
Pentamidine—Cough—Epirubicin—thyroid cancer	0.000371	0.000922	CcSEcCtD
Pentamidine—Vision blurred—Doxorubicin—thyroid cancer	0.00037	0.000921	CcSEcCtD
Pentamidine—Convulsion—Epirubicin—thyroid cancer	0.000368	0.000915	CcSEcCtD
Pentamidine—Hypertension—Epirubicin—thyroid cancer	0.000367	0.000912	CcSEcCtD
Pentamidine—Anaemia—Doxorubicin—thyroid cancer	0.000363	0.000903	CcSEcCtD
Pentamidine—Chest pain—Epirubicin—thyroid cancer	0.000361	0.000899	CcSEcCtD
Pentamidine—Arthralgia—Epirubicin—thyroid cancer	0.000361	0.000899	CcSEcCtD
Pentamidine—Myalgia—Epirubicin—thyroid cancer	0.000361	0.000899	CcSEcCtD
Pentamidine—Anxiety—Epirubicin—thyroid cancer	0.00036	0.000896	CcSEcCtD
Pentamidine—Discomfort—Epirubicin—thyroid cancer	0.000357	0.000888	CcSEcCtD
Pentamidine—CYP3A5—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000356	0.00412	CbGpPWpGaD
Pentamidine—Dry mouth—Epirubicin—thyroid cancer	0.000354	0.000879	CcSEcCtD
Pentamidine—Vertigo—Doxorubicin—thyroid cancer	0.000353	0.000878	CcSEcCtD
Pentamidine—Syncope—Doxorubicin—thyroid cancer	0.000352	0.000876	CcSEcCtD
Pentamidine—Leukopenia—Doxorubicin—thyroid cancer	0.000352	0.000875	CcSEcCtD
Pentamidine—Confusional state—Epirubicin—thyroid cancer	0.000349	0.000869	CcSEcCtD
Pentamidine—Palpitations—Doxorubicin—thyroid cancer	0.000347	0.000864	CcSEcCtD
Pentamidine—Anaphylactic shock—Epirubicin—thyroid cancer	0.000347	0.000862	CcSEcCtD
Pentamidine—S100B—Signaling by ERBB4—NRAS—thyroid cancer	0.000346	0.004	CbGpPWpGaD
Pentamidine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000345	0.000859	CcSEcCtD
Pentamidine—Infection—Epirubicin—thyroid cancer	0.000344	0.000856	CcSEcCtD
Pentamidine—Cough—Doxorubicin—thyroid cancer	0.000343	0.000853	CcSEcCtD
Pentamidine—Shock—Epirubicin—thyroid cancer	0.000341	0.000848	CcSEcCtD
Pentamidine—Convulsion—Doxorubicin—thyroid cancer	0.00034	0.000847	CcSEcCtD
Pentamidine—CYP2C19—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00034	0.00393	CbGpPWpGaD
Pentamidine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000339	0.000844	CcSEcCtD
Pentamidine—Hypertension—Doxorubicin—thyroid cancer	0.000339	0.000844	CcSEcCtD
Pentamidine—Tachycardia—Epirubicin—thyroid cancer	0.000338	0.000841	CcSEcCtD
Pentamidine—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000338	0.00391	CbGpPWpGaD
Pentamidine—CYP1A1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000337	0.00389	CbGpPWpGaD
Pentamidine—Myalgia—Doxorubicin—thyroid cancer	0.000334	0.000832	CcSEcCtD
Pentamidine—Arthralgia—Doxorubicin—thyroid cancer	0.000334	0.000832	CcSEcCtD
Pentamidine—Chest pain—Doxorubicin—thyroid cancer	0.000334	0.000832	CcSEcCtD
Pentamidine—Anxiety—Doxorubicin—thyroid cancer	0.000333	0.000829	CcSEcCtD
Pentamidine—S100B—Innate Immune System—CDK1—thyroid cancer	0.000332	0.00384	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—MINPP1—thyroid cancer	0.000331	0.00383	CbGpPWpGaD
Pentamidine—Discomfort—Doxorubicin—thyroid cancer	0.00033	0.000822	CcSEcCtD
Pentamidine—Anorexia—Epirubicin—thyroid cancer	0.00033	0.000822	CcSEcCtD
Pentamidine—Dry mouth—Doxorubicin—thyroid cancer	0.000327	0.000814	CcSEcCtD
Pentamidine—Hypotension—Epirubicin—thyroid cancer	0.000324	0.000805	CcSEcCtD
Pentamidine—Confusional state—Doxorubicin—thyroid cancer	0.000323	0.000804	CcSEcCtD
Pentamidine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000321	0.000798	CcSEcCtD
Pentamidine—S100B—Innate Immune System—IFNA2—thyroid cancer	0.000319	0.00369	CbGpPWpGaD
Pentamidine—Infection—Doxorubicin—thyroid cancer	0.000319	0.000792	CcSEcCtD
Pentamidine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000316	0.000785	CcSEcCtD
Pentamidine—Shock—Doxorubicin—thyroid cancer	0.000315	0.000785	CcSEcCtD
Pentamidine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000314	0.000781	CcSEcCtD
Pentamidine—Insomnia—Epirubicin—thyroid cancer	0.000313	0.00078	CcSEcCtD
Pentamidine—Tachycardia—Doxorubicin—thyroid cancer	0.000313	0.000778	CcSEcCtD
Pentamidine—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000312	0.00361	CbGpPWpGaD
Pentamidine—Paraesthesia—Epirubicin—thyroid cancer	0.000311	0.000774	CcSEcCtD
Pentamidine—Dyspnoea—Epirubicin—thyroid cancer	0.000309	0.000768	CcSEcCtD
Pentamidine—CYP2C8—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000309	0.00357	CbGpPWpGaD
Pentamidine—Somnolence—Epirubicin—thyroid cancer	0.000308	0.000766	CcSEcCtD
Pentamidine—Anorexia—Doxorubicin—thyroid cancer	0.000306	0.00076	CcSEcCtD
Pentamidine—Dyspepsia—Epirubicin—thyroid cancer	0.000305	0.000759	CcSEcCtD
Pentamidine—Decreased appetite—Epirubicin—thyroid cancer	0.000301	0.000749	CcSEcCtD
Pentamidine—Hypotension—Doxorubicin—thyroid cancer	0.0003	0.000745	CcSEcCtD
Pentamidine—Fatigue—Epirubicin—thyroid cancer	0.000299	0.000743	CcSEcCtD
Pentamidine—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000298	0.00345	CbGpPWpGaD
Pentamidine—S100B—Signaling by ERBB4—KRAS—thyroid cancer	0.000298	0.00344	CbGpPWpGaD
Pentamidine—Constipation—Epirubicin—thyroid cancer	0.000296	0.000737	CcSEcCtD
Pentamidine—Pain—Epirubicin—thyroid cancer	0.000296	0.000737	CcSEcCtD
Pentamidine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000292	0.000727	CcSEcCtD
Pentamidine—Insomnia—Doxorubicin—thyroid cancer	0.00029	0.000721	CcSEcCtD
Pentamidine—Paraesthesia—Doxorubicin—thyroid cancer	0.000288	0.000716	CcSEcCtD
Pentamidine—Dyspnoea—Doxorubicin—thyroid cancer	0.000286	0.000711	CcSEcCtD
Pentamidine—Feeling abnormal—Epirubicin—thyroid cancer	0.000286	0.00071	CcSEcCtD
Pentamidine—S100B—Immune System—TPR—thyroid cancer	0.000285	0.0033	CbGpPWpGaD
Pentamidine—Somnolence—Doxorubicin—thyroid cancer	0.000285	0.000709	CcSEcCtD
Pentamidine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000283	0.000705	CcSEcCtD
Pentamidine—S100B—Immune System—LGALS3—thyroid cancer	0.000283	0.00327	CbGpPWpGaD
Pentamidine—Dyspepsia—Doxorubicin—thyroid cancer	0.000282	0.000702	CcSEcCtD
Pentamidine—CYP4A11—Metabolism—NDUFA13—thyroid cancer	0.000281	0.00326	CbGpPWpGaD
Pentamidine—S100B—Immune System—PRKAR1A—thyroid cancer	0.000281	0.00325	CbGpPWpGaD
Pentamidine—Decreased appetite—Doxorubicin—thyroid cancer	0.000279	0.000693	CcSEcCtD
Pentamidine—Fatigue—Doxorubicin—thyroid cancer	0.000276	0.000688	CcSEcCtD
Pentamidine—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000275	0.00319	CbGpPWpGaD
Pentamidine—Urticaria—Epirubicin—thyroid cancer	0.000275	0.000685	CcSEcCtD
Pentamidine—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000274	0.00317	CbGpPWpGaD
Pentamidine—Pain—Doxorubicin—thyroid cancer	0.000274	0.000682	CcSEcCtD
Pentamidine—Constipation—Doxorubicin—thyroid cancer	0.000274	0.000682	CcSEcCtD
Pentamidine—Abdominal pain—Epirubicin—thyroid cancer	0.000274	0.000681	CcSEcCtD
Pentamidine—Body temperature increased—Epirubicin—thyroid cancer	0.000274	0.000681	CcSEcCtD
Pentamidine—S100B—Innate Immune System—NRG1—thyroid cancer	0.000266	0.00308	CbGpPWpGaD
Pentamidine—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000265	0.00306	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—CHST14—thyroid cancer	0.000265	0.00306	CbGpPWpGaD
Pentamidine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000264	0.000657	CcSEcCtD
Pentamidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000263	0.00305	CbGpPWpGaD
Pentamidine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000262	0.000652	CcSEcCtD
Pentamidine—CYP1A1—PPARA activates gene expression—RXRA—thyroid cancer	0.000256	0.00296	CbGpPWpGaD
Pentamidine—Hypersensitivity—Epirubicin—thyroid cancer	0.000255	0.000635	CcSEcCtD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000255	0.00295	CbGpPWpGaD
Pentamidine—Urticaria—Doxorubicin—thyroid cancer	0.000255	0.000634	CcSEcCtD
Pentamidine—Body temperature increased—Doxorubicin—thyroid cancer	0.000253	0.00063	CcSEcCtD
Pentamidine—Abdominal pain—Doxorubicin—thyroid cancer	0.000253	0.00063	CcSEcCtD
Pentamidine—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000253	0.00293	CbGpPWpGaD
Pentamidine—S100B—Signaling by ERBB4—HRAS—thyroid cancer	0.000253	0.00293	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—TCF7L1—thyroid cancer	0.000252	0.00291	CbGpPWpGaD
Pentamidine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.00025	0.00289	CbGpPWpGaD
Pentamidine—Asthenia—Epirubicin—thyroid cancer	0.000249	0.000618	CcSEcCtD
Pentamidine—Pruritus—Epirubicin—thyroid cancer	0.000245	0.00061	CcSEcCtD
Pentamidine—CYP1A1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000239	0.00276	CbGpPWpGaD
Pentamidine—Diarrhoea—Epirubicin—thyroid cancer	0.000237	0.00059	CcSEcCtD
Pentamidine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000236	0.000588	CcSEcCtD
Pentamidine—Asthenia—Doxorubicin—thyroid cancer	0.00023	0.000572	CcSEcCtD
Pentamidine—Dizziness—Epirubicin—thyroid cancer	0.000229	0.00057	CcSEcCtD
Pentamidine—Pruritus—Doxorubicin—thyroid cancer	0.000227	0.000564	CcSEcCtD
Pentamidine—S100B—Signaling by ERBB4—AKT1—thyroid cancer	0.000224	0.00259	CbGpPWpGaD
Pentamidine—Vomiting—Epirubicin—thyroid cancer	0.00022	0.000548	CcSEcCtD
Pentamidine—Diarrhoea—Doxorubicin—thyroid cancer	0.000219	0.000546	CcSEcCtD
Pentamidine—CYP2C8—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000219	0.00253	CbGpPWpGaD
Pentamidine—Rash—Epirubicin—thyroid cancer	0.000218	0.000543	CcSEcCtD
Pentamidine—Dermatitis—Epirubicin—thyroid cancer	0.000218	0.000543	CcSEcCtD
Pentamidine—Headache—Epirubicin—thyroid cancer	0.000217	0.00054	CcSEcCtD
Pentamidine—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000215	0.00248	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—HPGD—thyroid cancer	0.000213	0.00247	CbGpPWpGaD
Pentamidine—Dizziness—Doxorubicin—thyroid cancer	0.000212	0.000527	CcSEcCtD
Pentamidine—Nausea—Epirubicin—thyroid cancer	0.000206	0.000512	CcSEcCtD
Pentamidine—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000204	0.00236	CbGpPWpGaD
Pentamidine—Vomiting—Doxorubicin—thyroid cancer	0.000204	0.000507	CcSEcCtD
Pentamidine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000203	0.00235	CbGpPWpGaD
Pentamidine—Rash—Doxorubicin—thyroid cancer	0.000202	0.000503	CcSEcCtD
Pentamidine—Dermatitis—Doxorubicin—thyroid cancer	0.000202	0.000502	CcSEcCtD
Pentamidine—Headache—Doxorubicin—thyroid cancer	0.000201	0.0005	CcSEcCtD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000198	0.0023	CbGpPWpGaD
Pentamidine—CYP2C19—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000195	0.00226	CbGpPWpGaD
Pentamidine—S100B—Immune System—CDK1—thyroid cancer	0.000193	0.00224	CbGpPWpGaD
Pentamidine—Nausea—Doxorubicin—thyroid cancer	0.00019	0.000474	CcSEcCtD
Pentamidine—CYP1A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00019	0.0022	CbGpPWpGaD
Pentamidine—CYP3A5—Biological oxidations—RXRA—thyroid cancer	0.000189	0.00219	CbGpPWpGaD
Pentamidine—S100B—Immune System—IFNA2—thyroid cancer	0.000186	0.00215	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—TSHR—thyroid cancer	0.000184	0.00213	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—PRKAR1A—thyroid cancer	0.000181	0.0021	CbGpPWpGaD
Pentamidine—CYP1A1—Biological oxidations—RXRA—thyroid cancer	0.000179	0.00207	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000174	0.00202	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—MEN1—thyroid cancer	0.000173	0.00201	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000173	0.002	CbGpPWpGaD
Pentamidine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000172	0.00199	CbGpPWpGaD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000171	0.00198	CbGpPWpGaD
Pentamidine—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000166	0.00192	CbGpPWpGaD
Pentamidine—CYP2C8—Biological oxidations—RXRA—thyroid cancer	0.000164	0.0019	CbGpPWpGaD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000163	0.00188	CbGpPWpGaD
Pentamidine—CYP1A1—PPARA activates gene expression—PPARG—thyroid cancer	0.000161	0.00187	CbGpPWpGaD
Pentamidine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000158	0.00183	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—PTCH1—thyroid cancer	0.000157	0.00181	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000156	0.0018	CbGpPWpGaD
Pentamidine—S100B—Immune System—NRG1—thyroid cancer	0.000155	0.00179	CbGpPWpGaD
Pentamidine—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000152	0.00176	CbGpPWpGaD
Pentamidine—CYP2C19—Biological oxidations—RXRA—thyroid cancer	0.000146	0.00169	CbGpPWpGaD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000145	0.00168	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—SST—thyroid cancer	0.000143	0.00166	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—MINPP1—thyroid cancer	0.000139	0.00161	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—CALCA—thyroid cancer	0.000138	0.0016	CbGpPWpGaD
Pentamidine—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000135	0.00156	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—PTEN—thyroid cancer	0.000133	0.00154	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—MINPP1—thyroid cancer	0.000131	0.00152	CbGpPWpGaD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000127	0.00146	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—CDK1—thyroid cancer	0.000125	0.00145	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—TPR—thyroid cancer	0.000123	0.00142	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000121	0.0014	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—PRKAR1A—thyroid cancer	0.000121	0.00139	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—MINPP1—thyroid cancer	0.00012	0.00139	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—NRAS—thyroid cancer	0.000119	0.00138	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—NDUFA13—thyroid cancer	0.000118	0.00137	CbGpPWpGaD
Pentamidine—CYP1A2—Biological oxidations—RXRA—thyroid cancer	0.000114	0.00132	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—NDUFA13—thyroid cancer	0.000112	0.00129	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—CHST14—thyroid cancer	0.000111	0.00129	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000109	0.00126	CbGpPWpGaD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000109	0.00126	CbGpPWpGaD
Pentamidine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000109	0.00126	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—MINPP1—thyroid cancer	0.000107	0.00124	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—CHST14—thyroid cancer	0.000105	0.00121	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—KRAS—thyroid cancer	0.000102	0.00118	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—NDUFA13—thyroid cancer	0.000102	0.00118	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—NRG1—thyroid cancer	0.0001	0.00116	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—MINPP1—thyroid cancer	9.89e-05	0.00114	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—CHST14—thyroid cancer	9.63e-05	0.00111	CbGpPWpGaD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	9.26e-05	0.00107	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—SLC5A5—thyroid cancer	9.17e-05	0.00106	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—NDUFA13—thyroid cancer	9.14e-05	0.00106	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—TERT—thyroid cancer	9.01e-05	0.00104	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—HPGD—thyroid cancer	8.96e-05	0.00104	CbGpPWpGaD
Pentamidine—CYP3A4—Biological oxidations—RXRA—thyroid cancer	8.8e-05	0.00102	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—HRAS—thyroid cancer	8.71e-05	0.00101	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—HIF1A—thyroid cancer	8.61e-05	0.000996	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	8.59e-05	0.000994	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—CHST14—thyroid cancer	8.59e-05	0.000994	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—HPGD—thyroid cancer	8.46e-05	0.000979	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—NDUFA13—thyroid cancer	8.41e-05	0.000972	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—MINPP1—thyroid cancer	8.38e-05	0.000969	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—CHST14—thyroid cancer	7.9e-05	0.000914	CbGpPWpGaD
Pentamidine—S100B—Immune System—PTEN—thyroid cancer	7.77e-05	0.000899	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—HPGD—thyroid cancer	7.76e-05	0.000898	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—RXRA—thyroid cancer	7.7e-05	0.000891	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—AKT1—thyroid cancer	7.69e-05	0.000889	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	7.49e-05	0.000867	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—BRAF—thyroid cancer	7.13e-05	0.000825	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—NDUFA13—thyroid cancer	7.12e-05	0.000824	CbGpPWpGaD
Pentamidine—S100B—Immune System—NRAS—thyroid cancer	6.93e-05	0.000802	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—HPGD—thyroid cancer	6.93e-05	0.000801	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.87e-05	0.000794	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—CHST14—thyroid cancer	6.7e-05	0.000774	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—MINPP1—thyroid cancer	6.46e-05	0.000748	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—HPGD—thyroid cancer	6.37e-05	0.000737	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.29e-05	0.000728	CbGpPWpGaD
Pentamidine—S100B—Immune System—KRAS—thyroid cancer	5.97e-05	0.00069	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.62e-05	0.00065	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—NDUFA13—thyroid cancer	5.5e-05	0.000636	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—HPGD—thyroid cancer	5.4e-05	0.000624	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—CCND1—thyroid cancer	5.2e-05	0.000602	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—CHST14—thyroid cancer	5.17e-05	0.000598	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—TPR—thyroid cancer	5.15e-05	0.000595	CbGpPWpGaD
Pentamidine—S100B—Immune System—HRAS—thyroid cancer	5.07e-05	0.000587	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	5.06e-05	0.000586	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—PTEN—thyroid cancer	5.02e-05	0.000581	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—PPARG—thyroid cancer	4.86e-05	0.000563	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—TPR—thyroid cancer	4.86e-05	0.000562	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—PRKAR1A—thyroid cancer	4.78e-05	0.000553	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—NRAS—thyroid cancer	4.48e-05	0.000518	CbGpPWpGaD
Pentamidine—S100B—Immune System—AKT1—thyroid cancer	4.48e-05	0.000518	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—TPR—thyroid cancer	4.46e-05	0.000516	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	4.38e-05	0.000507	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.38e-05	0.000506	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.33e-05	0.000501	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—HPGD—thyroid cancer	4.17e-05	0.000482	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—TPR—thyroid cancer	3.98e-05	0.00046	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.97e-05	0.00046	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	3.91e-05	0.000453	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—KRAS—thyroid cancer	3.86e-05	0.000446	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—SLC5A5—thyroid cancer	3.85e-05	0.000446	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—PTGS2—thyroid cancer	3.83e-05	0.000443	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—TPR—thyroid cancer	3.66e-05	0.000423	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—SLC5A5—thyroid cancer	3.64e-05	0.000421	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	3.6e-05	0.000416	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.55e-05	0.00041	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—TP53—thyroid cancer	3.43e-05	0.000397	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.41e-05	0.000394	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—PTEN—thyroid cancer	3.34e-05	0.000386	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—SLC5A5—thyroid cancer	3.34e-05	0.000386	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—HRAS—thyroid cancer	3.28e-05	0.000379	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—RXRA—thyroid cancer	3.24e-05	0.000374	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.13e-05	0.000362	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—TPR—thyroid cancer	3.1e-05	0.000359	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—RXRA—thyroid cancer	3.06e-05	0.000354	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	3.05e-05	0.000353	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—SLC5A5—thyroid cancer	2.98e-05	0.000344	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.97e-05	0.000344	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—AKT1—thyroid cancer	2.9e-05	0.000335	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—RXRA—thyroid cancer	2.8e-05	0.000324	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.79e-05	0.000323	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.76e-05	0.00032	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—SLC5A5—thyroid cancer	2.74e-05	0.000317	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.73e-05	0.000315	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—RXRA—thyroid cancer	2.5e-05	0.000289	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.43e-05	0.000281	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—TPR—thyroid cancer	2.39e-05	0.000277	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	2.35e-05	0.000272	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—SLC5A5—thyroid cancer	2.32e-05	0.000268	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—RXRA—thyroid cancer	2.3e-05	0.000266	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.17e-05	0.000252	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—PPARG—thyroid cancer	2.04e-05	0.000236	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—RXRA—thyroid cancer	1.95e-05	0.000226	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—PPARG—thyroid cancer	1.93e-05	0.000223	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—AKT1—thyroid cancer	1.92e-05	0.000222	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.9e-05	0.000219	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.79e-05	0.000207	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—PPARG—thyroid cancer	1.77e-05	0.000205	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—PTGS2—thyroid cancer	1.61e-05	0.000186	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—PPARG—thyroid cancer	1.58e-05	0.000183	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—PTGS2—thyroid cancer	1.52e-05	0.000176	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—RXRA—thyroid cancer	1.5e-05	0.000174	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—PPARG—thyroid cancer	1.45e-05	0.000168	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—PTEN—thyroid cancer	1.4e-05	0.000162	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—PTGS2—thyroid cancer	1.39e-05	0.000161	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—PTEN—thyroid cancer	1.32e-05	0.000153	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—PTGS2—thyroid cancer	1.24e-05	0.000144	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—PPARG—thyroid cancer	1.23e-05	0.000142	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—PTEN—thyroid cancer	1.21e-05	0.00014	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—PTGS2—thyroid cancer	1.14e-05	0.000132	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—PTEN—thyroid cancer	1.08e-05	0.000125	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—PTEN—thyroid cancer	9.97e-06	0.000115	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—PTGS2—thyroid cancer	9.68e-06	0.000112	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—PPARG—thyroid cancer	9.5e-06	0.00011	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—PTEN—thyroid cancer	8.44e-06	9.77e-05	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—AKT1—thyroid cancer	8.08e-06	9.35e-05	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—AKT1—thyroid cancer	7.63e-06	8.83e-05	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—PTGS2—thyroid cancer	7.47e-06	8.64e-05	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—AKT1—thyroid cancer	7e-06	8.09e-05	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—PTEN—thyroid cancer	6.52e-06	7.54e-05	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—AKT1—thyroid cancer	6.25e-06	7.22e-05	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—AKT1—thyroid cancer	5.74e-06	6.65e-05	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—AKT1—thyroid cancer	4.87e-06	5.63e-05	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—AKT1—thyroid cancer	3.76e-06	4.34e-05	CbGpPWpGaD
